GlassScriptPhysician profile
Robert A Mevorach
NPI 1265471536
$896.30
in general payments reported to CMS, 2019-2025
14 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Pediatric Urology provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.97 · 2022: $118 · 2023: $399 · 2024: $183 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $232.87 | 2024-2025 | Perclot, Floseal |
| Abbvie INC. | $149.16 | 2022-2024 | |
| Karl Storz Endoscopy-America | $111.83 | 2023 | N.A. |
| Endo Pharmaceuticals INC. | $89.60 | 2023 | Xiaflex, Aveed, Edex |
| Intuitive Surgical, INC. | $79.00 | 2023 | Da Vinci Surgical System |
| Rochester Medical Corporation | $67.01 | 2022 | |
| Janssen Biotech, INC. | $44.36 | 2021 | |
| Dendreon Pharmaceuticals LLC | $23.11 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.40 | 2023 | Givlaari |
| Medtronic, INC. | $18.60 | 2024 | Interstim |
| Boston Scientific Corporation | $16.42 | 2023 | |
| Ambu INC. | $15.33 | 2022 | |
| Allergan, INC. | $14.84 | 2021 | |
| Myovant Sciences INC. | $14.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mevorach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.